Neoadjuvant therapy in breast cancer is a hot topic these days. Giving drugs in the neoadjuvant setting has several advantages:
Eleonora Teplinsky, MD
The majority of breast cancers are hormone-receptor (HR) positive. Sixty to 75% of women have estrogen receptor (ER)-positive breast cancer, and 65% of these cancers are also progesterone receptor (PR)-positive.
Targeting angiogenesis in cancer dates back to the 1970s, when the first anti-angiogenesis inhibitor, bevacizumab, was described to “starve tumors.” Of course in breast cancer, there was a lot of excitement when bevacizumab was granted ac